Literature DB >> 14702109

Critical roles of TRAIL in hepatic cell death and hepatic inflammation.

Shi-Jun Zheng1, Pu Wang, Galit Tsabary, Youhai H Chen.   

Abstract

The TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not most normal cells. Its role in hepatic cell death and hepatic diseases is not clear. In vitro studies suggest that murine hepatocytes are not sensitive to TRAIL-induced apoptosis, indicating that TRAIL may not mediate hepatic cell death. Using two experimental models of hepatitis, we found that hepatic cell death in vivo was dramatically reduced in TRAIL-deficient mice and mice treated with a blocking TRAIL receptor. Although both TRAIL and its death receptor 5 were constitutively expressed in the liver, TRAIL expression by immune cells alone was sufficient to restore the sensitivity of TRAIL-deficient mice to hepatitis. Thus, TRAIL plays a crucial role in hepatic cell death and hepatic inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702109      PMCID: PMC300768          DOI: 10.1172/JCI19255

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer.

Authors:  N Chirmule; A D Moscioni; Y Qian; R Qian; Y Chen; J M Wilson
Journal:  Hum Gene Ther       Date:  1999-01-20       Impact factor: 5.695

2.  Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis.

Authors:  R Ksontini; D B Colagiovanni; M D Josephs; C K Edwards; C L Tannahill; C C Solorzano; J Norman; W Denham; M Clare-Salzler; S L MacKay; L L Moldawer
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

3.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Authors:  H Walczak; R E Miller; K Ariail; B Gliniak; T S Griffith; M Kubin; W Chin; J Jones; A Woodward; T Le; C Smith; P Smolak; R G Goodwin; C T Rauch; J C Schuh; D H Lynch
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Authors:  J G Emery; P McDonnell; M B Burke; K C Deen; S Lyn; C Silverman; E Dul; E R Appelbaum; C Eichman; R DiPrinzio; R A Dodds; I E James; M Rosenberg; J C Lee; P R Young
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

5.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  M Jo; T H Kim; D W Seol; J E Esplen; K Dorko; T R Billiar; S C Strom
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

6.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

Authors:  K Ichikawa; W Liu; L Zhao; Z Wang; D Liu; T Ohtsuka; H Zhang; J D Mountz; W J Koopman; R P Kimberly; T Zhou
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

7.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.

Authors:  G S Wu; T F Burns; Y Zhan; E S Alnemri; W S El-Deiry
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

8.  CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons.

Authors:  A Martin-Villalba; I Herr; I Jeremias; M Hahne; R Brandt; J Vogel; J Schenkel; T Herdegen; K M Debatin
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

9.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

Authors:  P Schneider; M Thome; K Burns; J L Bodmer; K Hofmann; T Kataoka; N Holler; J Tschopp
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

10.  Safety and antitumor activity of recombinant soluble Apo2 ligand.

Authors:  A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

View more
  60 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

Review 3.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver.

Authors:  S C Afford; D H Adams
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

4.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

6.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.

Authors:  Harmeet Malhi; Fernando J Barreyro; Hajime Isomoto; Steven F Bronk; Gregory J Gores
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

8.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

Review 9.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 10.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.